Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Premarket analyst action - healthcare

Published 04/04/2018, 08:26 AM
Updated 04/04/2018, 08:26 AM
© Reuters. Premarket analyst action - healthcare
  • Dexcom (NASDAQ:DXCM) initiated with a Sell rating and $57 (24% downside risk) price target at Goldman Sachs (NYSE:GS). Initiated with Neutral rating at Guggenheim. Shares down 5% premarket.
  • NuVasive (NASDAQ:NUVA) initiated with Neutral rating and $47 (12% downside risk) price target at Goldman.
  • Nevro (NYSE:NVRO) initiated with Neutral rating and $83 (4% downside risk) price target at Goldman.
  • Hill-Rom Holdings (NYSE:HRC) initiated with Neutral rating and $85 (2% downside risk) price target at Goldman.
  • ABIOMED (NASDAQ:ABMD) initiated with Buy rating and $332 (19% upside) price target at Goldman.
  • Penumbra (NYSE:PEN) initiated with Buy rating and $145 (28% upside) price target at Goldman.
  • Insulet (NASDAQ:PODD) initiated with Buy rating and $105 (24% upside) price target at Guggenheim.
  • Adamas Pharmaceuticals (NASDAQ:ADMS) initiated with Outperform rating and $31 (26% upside) price target at Leerink.
  • Senseonics Holdings (NYSEMKT:SENS) initiated with Buy rating and $6 (97% upside) price target at Guggenheim.
  • Vericel (NASDAQ:VCEL) initiated with Outperform rating and $15 (55% upside) price target at Leerink.
  • The Cooper Companies (NYSE:COO) resumed with Neutral rating and $231 (5% upside) price target at Goldman.
  • Globus Medical (NYSE:GMED) upgraded to Buy with a $57 (16% upside) price target at Needham.
  • Henry Schein (NASDAQ:HSIC) upgraded to Outperform at Leerink.
  • GlaxoSmithKline (NYSE:GSK) upgraded to Outperform at Exane BNP Paribas (PA:BNPP).
  • UroGen Pharma (NASDAQ:URGN) upgraded to Outperform with a $73 (22% upside) price target at Raymond James.
  • AnaptysBio (NASDAQ:ANAB) downgraded to Sector Perform at RBC Capital Markets.
  • Endo International (NASDAQ:ENDP) downgraded to Neutral with a $7 (22% upside) price target at Mizuho.
  • PTC Therapeutics (NASDAQ:PTCT) downgraded to Underweight with $26 (flat) price target at Barclays (LON:BARC) citing lack of revenue upside. Shares down 6% premarket.
  • Now read: President Trump Considers Suing Opioid Manufacturers
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.